<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec has submitted an initial disclosure to the stock exchanges confirming that it does not qualify as a 'Large Corporate' under SEBI's framework for fund raising through debt securities. As of March 31, 2025, the company's outstanding long-term borrowings stand at only Rs. 15 crore, well below the threshold required for Large Corporate classification. The company has not availed any bank facilities and therefore does not carry any credit rating from a rating agency. The disclosure was signed by Group CFO Vinod Goel and CFO Devender Gupta. This is a routine annual compliance filing mandated under SEBI's operational circular on debt issuance by large entities.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms that Panacea Biotec's debt levels are too low to trigger additional borrowing or disclosure obligations under SEBI's Large Corporate framework.